Myriad Genetics, Inc. (MYGN) stock moved with shift of 3.84% in the past week. …
Myriad Genetics Inc. now has a P/E ratio of 90. For a complete fundamental analysis analysis of Myriad Genetics Inc., check out Equities.com’s Stock Valuation Analysis report for MYGN. Myriad Genetics Inc is a molecular diagnostic …
Collecting that bid as the premium represents a 6% return against the $24 commitment, or a 12.1% annualized rate of return (at Stock Options Channel we call this the YieldBoost). Selling a put does not give an investor access to …
At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk …
The stock’s market capitalization is 1.98B, it has a 52-week low of 15.15 and a 52-week high of 29.30. The share price of the company (NASDAQ:MYGN) was up +0.07%, with a high of 29.16 during the day and the volume of Myriad …
(NASDAQ:MYGN). First Tru Advisors Ltd Partnership has invested 0.07% in Myriad Genetics, Inc. It has underperformed by 54.17% the S&P500. Two equities research analysts have rated the stock with a sell rating, eight have given a hold …
SmarTrend identified an Uptrend for Myriad Genetics (NASDAQ:MYGN) on May 3rd, 2017 at $21.49. In approximately 3 months, Myriad Genetics has returned 30.17% as of today's recent price of $27.98. In the past 52 weeks, shares of …
Myriad Genetics Inc. (MYGN) reported fourth quarter EPS of $0.30 after the bell ... Shares finished up by 2.43 at $27.98 on above average volume. The stock broke out of a month and a half long trading range and set nearly a 52-week high.
While issues with intellectual property and the ensuing generic threat are a concern, if positive data comes later on it's a decent bet that the stock price could double or more. Myriad Genetics (MYGN) The fund added slightly to this position, …